Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Sattler

Showing results (21-30 of 130) with videos related to

Pageof 13
Sort By:
Expert Opinion on Therapeutic Targets|February 21, 2012
Targeting JAK2 in the therapy of myeloproliferative neoplasmsMamatha M Reddy, Anagha Deshpande, Martin Sattler
Antioxidants & Redox Signaling|July 3, 2008
Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implicationsMargret S Rodrigues, Mamatha M Reddy, Martin Sattler
Trends in Cancer|February 8, 2023
Precision oncology provides opportunities for targeting KRAS-inhibitor resistanceMartin Sattler, Atish Mohanty, Prakash Kulkarni, et al.
Frontiers in Pharmacology|January 24, 2022
Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural MesotheliomaMoshe Lapidot, Srinivas Vinod Saladi, Ravi Salgia, et al.
Advances in Experimental Medicine and Biology|August 12, 2003
Mutated tyrosine kinases as therapeutic targets in myeloid leukemiasMartin Sattler, Blanca Scheijen, Ellen Weisberg, et al.
Hematology Reports|November 21, 2023
Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia: Trials and TribulationsSwati Garg, Wei Ni, James D Griffin, et al.
Biochemistry|December 1, 2017
Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological Malignancies<sub>Published as part of the Biochemistry series "Biochemistry to Bedside"</sub>Paul W Manley, Ellen Weisberg, Martin Sattler, et al.
Oncotargets and Therapy|January 19, 2018
Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapyEllen Weisberg, Martin Sattler, Paul W Manley, et al.
Journal of Dermatological Science|May 19, 2016
Inhibition of Propionibacterium acnes associated biofilm formation by DecanediolMelanie Sulzberger, Heike Fölster, Martin Sattler, et al.
Cell Reports. Medicine|February 1, 2021
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)Ravi Salgia, Rebecca Pharaon, Isa Mambetsariev, et al.
Pageof 13

Showing results (21-30 of 130) with videos related to

Sort By:
Pageof 13
Expert Opinion on Therapeutic Targets|February 21, 2012
Targeting JAK2 in the therapy of myeloproliferative neoplasmsMamatha M Reddy, Anagha Deshpande, Martin Sattler
Antioxidants & Redox Signaling|July 3, 2008
Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implicationsMargret S Rodrigues, Mamatha M Reddy, Martin Sattler
Trends in Cancer|February 8, 2023
Precision oncology provides opportunities for targeting KRAS-inhibitor resistanceMartin Sattler, Atish Mohanty, Prakash Kulkarni, et al.
Frontiers in Pharmacology|January 24, 2022
Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural MesotheliomaMoshe Lapidot, Srinivas Vinod Saladi, Ravi Salgia, et al.
Advances in Experimental Medicine and Biology|August 12, 2003
Mutated tyrosine kinases as therapeutic targets in myeloid leukemiasMartin Sattler, Blanca Scheijen, Ellen Weisberg, et al.
Hematology Reports|November 21, 2023
Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia: Trials and TribulationsSwati Garg, Wei Ni, James D Griffin, et al.
Biochemistry|December 1, 2017
Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological Malignancies<sub>Published as part of the Biochemistry series "Biochemistry to Bedside"</sub>Paul W Manley, Ellen Weisberg, Martin Sattler, et al.
Oncotargets and Therapy|January 19, 2018
Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapyEllen Weisberg, Martin Sattler, Paul W Manley, et al.
Journal of Dermatological Science|May 19, 2016
Inhibition of Propionibacterium acnes associated biofilm formation by DecanediolMelanie Sulzberger, Heike Fölster, Martin Sattler, et al.
Cell Reports. Medicine|February 1, 2021
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)Ravi Salgia, Rebecca Pharaon, Isa Mambetsariev, et al.
Pageof 13